Fig. 8

ROS-responsive CRISPR-Cas9 delivery nanoformulations. A Process of preparation of the PPMMT complex: design of the plasmid encoding the dsCas9 sequence with DHFR domains, complexation with the cationic polymer (PBAE), coating with MMs derived from RAW264.7 cells, and anchoring of ROS-responsive BAM-TK-TMP on the membrane of PPMM to obtain PPMMT. B Illustration of targeted delivery and inflammation-specific genome editing in the inflammatory colon lesion: PPMMT targeting the inflammatory colons by virtue of MMs, plasmid translation into dsCas9, dsCas9 stabilized upon the released TMP to recover the genome-editing activity, and dsCas9 degradation in a ubiquitin-dependent proteasomal pathway in the noninflammatory tissues. Reproduced with permission [143]